EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 深圳市海王英特龍生物技術股份有限公司 | | 股份代號 | 08329 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度末期股息 | | 公告日期 | 2025年4月16日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 | 更新「股東批准日期」、「除淨日」、「為符合獲取股息分派而遞交股份過戶文件之最 後時限」、「暫停辦理股份過戶登記手續之日期」、「記錄日期」及「股息派發日」 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.005 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立的股份有限公司） （股份代號：8329） 股東週年大會通告 茲通告深圳市海王英特龍生物技術股份有限公司（「本公司」）股東週年大會（「大會」）謹訂於二零二五年 五月十三日（星期二）上午十時正假座中華人民共和國（「中國」）廣東省深圳市南山區粵海街道麻嶺社區 科技中三路1號海王銀河科技大廈24樓會議室舉行，藉以考慮及酌情通過下文所載決議案（不論修訂 與否）。除文義另有所指外，本公司日期為二零二五年四月十七日之通函（「通函」）中所定義詞彙與本 通告所載者具有相同涵義。 普通決議案 * 僅供識別 1 1. 審議及批准本公司及其附屬公司截至二零二四年十二月三十一日止年度的經審核綜合財務報 表。 2. 審議及批准本公司截至二零二四年十二月 ...

環境、社會及管治報告 2024 * 僅供識別之用 環境、社會及管治報告 目錄 | 3 | 一、 | 關於本報告 | | --- | --- | --- | | 6 | 二、 | 主席致辭 | | 7 | 三、 | 關於海王英特龍 | | 7 | | • 業務概覽 | | 8 | | • 企業文化 | | 9 | 四、 | 可持續發展理念及管治 | | 11 | 五、 | 持份者溝通 | | 14 | 六、 | 重要性評估 | | 18 | 七、 | 環境層面 | | 18 | | • A1：排放物 | | 21 | | • A2：資源使用 | | 24 | | • A3：環境及天然資源 | | 24 | | • A4：氣候變化 | 環境、社會及管治報告二零二四年 1 環境、社會及管治報告 | 27 | 八、 社會層面 | | --- | --- | | 27 | • B1：僱傭 & B4： 勞工準則 | | 31 | • B2：健康與安全 | | 32 | • B3：發展及培訓 | | 34 | • B5：供應鏈管理 | | 35 | B6：產品責任 • | | 38 | B7：反貪污 • | | 39 | ...

此乃要件 請即處理 閣下對本通函任何方面或應採取的行動如有任何疑問，應諮詢股票經紀或其他註冊證券交易 商、銀行經理、律師、專業會計師或其他專業顧問尋求獨立意見。 閣下如已售出或轉讓名下所有深圳市海王英特龍生物技術股份有限公司的股份，應立即將本通 函連同隨附的代理人委任表格交予買主、承讓人或經手買賣或轉讓的銀行、股票經紀或其他代 理人，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 深圳市海王英特龍生物技術股份有限公司 SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED* （於中華人民共和國註冊成立的股份有限公司） （股份代號：8329） (iii) 暫停辦理股份過戶登記手續 及 (iv) 股東週年大會通告 深圳市海王英特龍生物技術股份有限公司謹訂於二零二五年五月十三日（星期二）上午十時正假 座中華人民共和國（「中國」）廣東省深圳市南山區粵海街道麻嶺社區科技中三路1 ...

Industry Performance - In 2024, the pharmaceutical industry showed a steady recovery, but the sub-sectors of chemical preparations and Chinese medicines recorded negative growth in operating revenue and profit [17]. - The overall economic indicators of the pharmaceutical industry remained robust, with the medical device sub-sector maintaining growth in revenue and profit [17]. Profitability and Financial Performance - The Group faced significant pressure on profits due to the expansion of centralized drug procurement and increased market competition from innovative and generic drugs [17]. - The Group's total revenue for the Year was approximately RMB1,041,698,000, representing a decrease of approximately 2.18% compared to the previous year [50]. - The gross profit margin for the Year was approximately 32%, a decrease of approximately 10 percentage points from the previous year [51]. - The Group's gross profit for the Year was approximately RMB330,467,000, representing a decrease of approximately 26.15% compared to the previous year [56]. - Profit after tax decreased from approximately RMB14,526,000 to approximately RMB13,765,000, representing a decrease of approximately 5.23% [61]. - Profit attributable to the owners of the Company increased from approximately RMB24,127,000 to approximately RMB25,014,000, representing an increase of approximately 3.68% [61]. Strategic Adjustments and Development - The Group adjusted its development strategies by promoting sales through multiple channels, including hospital sales, chain drugstores, distribution, and e-commerce [18]. - The Group's strategic adjustments were aimed at reducing risks associated with industry policy changes and reliance on single sales channels [18]. - The Group accomplished its established operating objectives during the year while gradually implementing new strategies [18]. - The Group plans to focus on integrated planning and adjust sales strategies to stabilize its business amid adverse impacts from new healthcare reform policies [41]. - The Group is actively expanding its healthcare food market and medical device agency business to mitigate the impact of declining drug sales prices [20]. Research and Development - The Group continued to enhance its innovative capability through independent research and development and collaboration with external institutions [18]. - The Group's research and development efforts include independent projects and collaborations, focusing on new medicines and generic medicine consistency evaluations [30]. - The Group owns a total of 93 patents, including 31 invention patents, and has five products that have passed the consistency evaluation [30]. Production and Operations - The introduction of commissioned production and contract processing models aimed to improve production capacity utilization, reduce costs, and increase efficiency [18]. - The Group is enhancing its production capacity through contract manufacturing and processing models to improve efficiency and reduce costs [20]. - Neptunus Zhongxin improved its operating condition compared to the previous year by expanding production capacity and adjusting its product mix [36]. Employee and Management - The management team remains focused on employee compensation and benefits, ensuring alignment with business performance [94]. - The Company emphasizes training and development opportunities for employees to enhance their skills [94]. - The group employed a total of 1,485 staff as of December 31, 2024, compared to 1,444 in 2023 [87]. Dividends and Shareholder Returns - The Group plans to distribute its first final dividend and special dividend, which is expected to have no material adverse effect on its underlying assets and financial condition [23]. - The Board declared a final dividend of RMB0.005 per share and a special dividend of RMB0.141 per share for the year ended 31 December 2024, compared to no dividend for the year ended 31 December 2023 [96]. - The decision to distribute dividends was based on factors including cash flow and financial condition, acknowledging shareholder support [96]. Financial Management - Selling and distribution expenses for the Year were approximately RMB162,361,000, a decrease of approximately 35.78% compared to the previous year [57]. - Administrative expenses for the Year were approximately RMB93,912,000, an increase of approximately 3.85% compared to the previous year [58]. - The group's net current assets as of December 31, 2024, were approximately RMB 468,604,000, a decrease of about RMB 85,800,000 compared to RMB 554,404,000 as of December 31, 2023 [66]. - The gearing ratio as of December 31, 2024, was approximately 36.25%, down from 39.31% in 2023 [73]. Corporate Governance - The Company confirmed that it has received annual confirmations of independence from its independent non-executive directors [168]. - The Group has implemented Directors, Supervisors, and Senior Management Liability Insurance to provide appropriate coverage, excluding fraud or dishonesty matters [185]. - The Group regularly reviews its compensation and benefits policies to ensure competitiveness and compliance with local labor laws [178].

第 1 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 深圳市海王英特龍生物技術股份有限公司 | | 股份代號 | 08329 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度特別股息 | | 公告日期 | 2025年3月26日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 更新「派息金額及公司預設派發貨幣」及「匯率」 | | | 股息信息 | | | 股息類型 | 其他 | | 特別股息 | | | 股息性質 | 特別股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.141 RMB | | 股東批准日期 | 有待公佈 ...

發行人所發行上市權證/可轉換債券的相關信息 發行人所發行上市權證/可轉換債券 不適用 其他信息 其他信息 不適用 發行人董事 於本通告日期，執行董事為張鋒先生，黃劍波先生及張曉光先生，非執行董事為張翼飛先生、于琳女士及金銳先生，而獨立非執行 董事為易永發先生、潘嘉陽先生及章劍舟先生。 第 2 頁 共 2 頁 v 1.1.1 第 1 頁 共 2 頁 v 1.1.1 EF001 EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 深圳市海王英特龍生物技術股份有限公司 | | 股份代號 | 08329 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度末期股息 | | 公告日期 | 2025年3月26日 | | 公告狀態 | 更新公告 | | 更新/撤回理由 更新 ...

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 深圳市海王英特龍生物技術股份有限公司 | | 股份代號 | 08329 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度特別股息 | | 公告日期 | 2025年3月25日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 其他 | | 特別股息 | | | 股息性質 | 特別股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.141 RMB | | 股東批准日期 | 有待公佈 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.141 RMB | | 匯率 ...

EF001 免責聲明 EF001 其他信息 其他信息 不適用 發行人董事 於本公告日期，執行董事為張鋒先生，黃劍波先生及張曉光先生，非執行董事為張翼飛先生、于琳女士及金銳先生，而獨立非執行 董事為易永發先生、潘嘉陽先生及章劍舟先生。 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 深圳市海王英特龍生物技術股份有限公司 | | | 股份代號 | 08329 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2024年12月31日止年度末期股息 | | 公告日期 | 2025年3月25日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派 ...

Financial Performance - The company's revenue for the year ended December 31, 2024, was RMB 1,041,698,000, a decrease of 2.4% compared to RMB 1,064,861,000 in 2023[3] - Gross profit for the year was RMB 330,467,000, down 26.2% from RMB 447,511,000 in the previous year[3] - Operating profit decreased slightly to RMB 34,722,000 from RMB 36,248,000, reflecting a decline of 4.2%[3] - The net profit attributable to the owners of the company was RMB 25,014,000, an increase of 3.7% from RMB 24,127,000 in 2023[3] - Basic and diluted earnings per share increased to RMB 1.49 from RMB 1.44, representing a growth of 3.5%[3] - The company reported a total segment profit of RMB 37,179,000 for 2024, a decrease of 3.2% from RMB 38,419,000 in 2023[33] - The net profit after tax decreased to approximately RMB 13,765,000, down about 5.23% from the previous year[65] Assets and Liabilities - Total assets as of December 31, 2024, were RMB 1,398,086,000, compared to RMB 1,415,646,000 in 2023, indicating a slight decrease[4] - The company's cash and cash equivalents decreased to RMB 283,424,000 from RMB 372,206,000, a decline of 23.9%[4] - Non-current assets totaled RMB 589,059,000, an increase from RMB 495,062,000 in the previous year, reflecting a growth of 18.9%[4] - The company reported a total equity of RMB 1,026,099,000, up from RMB 1,016,182,000 in 2023, indicating a growth of 1.0%[5] - The company’s total liabilities decreased to RMB 222,377,000 in 2024 from RMB 260,527,000 in 2023, a reduction of about 14.6%[48] - Accounts receivable decreased to RMB 159,529,000 in 2024 from RMB 174,252,000 in 2023, a reduction of approximately 8.4%[46] Revenue Breakdown - Revenue from the production and sale of pharmaceuticals and medical devices was RMB 540,581,000 in 2024, down 6.3% from RMB 576,679,000 in 2023[26] - Revenue from the sale and distribution of pharmaceuticals, health products, and medical devices increased to RMB 501,117,000 in 2024, up 2.3% from RMB 488,182,000 in 2023[26] - The sales of medical devices accounted for approximately RMB 220,993,000 in 2024, compared to RMB 210,674,000 in 2023, reflecting a growth of 4.0%[27] - Revenue from hospitals was RMB 74,139,000 in 2024, while revenue from pharmacies was RMB 960,111,000, indicating a shift in sales channels[36] Expenses - Employee costs increased to RMB 163,778,000 in 2024 from RMB 148,985,000 in 2023, reflecting a rise of about 9.5%[37] - Research and development expenses decreased to RMB 33,130,000 in 2024 from RMB 46,203,000 in 2023, a decline of approximately 28.3%[39] - Sales and distribution expenses for the year were approximately RMB 162,361,000, a decrease of about 35.78% compared to the previous year[63] - Administrative expenses for the year were approximately RMB 93,912,000, an increase of 3.85% year-on-year[64] Dividends and Shareholder Information - The company plans to distribute a final dividend of RMB 0.005 per share and a special dividend of RMB 0.141 per share for 2024, totaling RMB 244,988,000[42][43] - Major shareholder Sea King Biological holds 1,181,000,000 shares, representing approximately 94.33% of domestic shares and 70.38% of total issued capital[88] - Sea King Group and Sea King Holdings each control 1,233,464,500 shares, accounting for 98.52% of domestic shares and 73.51% of total issued capital[88] Compliance and Governance - The financial statements comply with the applicable GEM Listing Rules disclosure requirements[10] - The board emphasizes adherence to corporate governance principles and has complied with applicable GEM listing rules[95] - The company has adopted a code of conduct for securities trading that meets or exceeds GEM listing rules standards[96] - The controlling shareholder, Sea King Biological, has committed not to engage in any business that competes directly or indirectly with the company[98] Future Plans and Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[7] - The company plans to continue transforming its marketing model and organizational structure to achieve profitability by 2025[57] - The company aims to enhance its product sales structure by shifting from traditional drug distribution to a model integrating medical services and drug distribution[57] - The company is actively expanding its market presence by participating in national procurement alliances, which could drive sales growth[56] Financial Reporting Standards - The consolidated financial statements are prepared in accordance with the Hong Kong Financial Reporting Standards and presented in Renminbi (RMB) as the functional currency[10] - The financial statements have been prepared on a historical cost basis, with no significant impact from the adoption of revised Hong Kong Financial Reporting Standards for the current and prior periods[11][12] - The revised Hong Kong Financial Reporting Standards effective from January 1, 2024, include HKAS 1 (Amendment) related to non-current liabilities with covenants and HKFRS 16 (Amendment) concerning lease liabilities in sale and leaseback transactions[12] - The company anticipates that the newly issued and revised Hong Kong Financial Reporting Standards will not have a significant impact on the consolidated financial statements[15] Employee and Workforce - The company employed a total of 1,485 employees as of December 31, 2024, compared to 1,444 employees in 2023, indicating a focus on workforce expansion[78] - The total employee cost for the year was approximately RMB 163,778,000, an increase from RMB 148,985,000 in 2023, reflecting adjustments in salaries and benefits to maintain competitiveness[78] Research and Development - The company has a total of 368 approved drug formulations at its Fuzhou production base, with 236 included in the National Basic Medical Insurance Drug List[53] - The company holds 87 patents, including 25 invention patents, indicating a strong focus on innovation and intellectual property[54] - Five products have passed the consistency evaluation, including sodium bicarbonate tablets and norfloxacin capsules, enhancing the company's market competitiveness[54] - The company aims to obtain production approval for its self-developed drugs by 2025, which could significantly impact future revenue streams[55] Miscellaneous - There were no significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the year[75] - The company reported no significant contingent liabilities as of December 31, 2024[76] - The company did not engage in any major investments or purchases of significant capital assets during the year[77] - The company has confirmed compliance with the non-competition commitment established with its controlling shareholder, Sea King Biological, during the year[94] - The group’s financial data for the year has been reviewed and is consistent with the audited consolidated financial statements[99]